LZD

AcronymDefinition
LZDLazordog
LZDLeading-Zero Detector
LZDLaser Zona Dissection
References in periodicals archive ?
Since 2006, the WHO has considered LZD for the treatment of MDR-TB, acknowledging that its efficacy is unclear and recommending against its routine use (13).
Drug MIC ([micro]g/mL) PCG >2 CTX >32 CTRX >2 cfpm >2 IPM >8 MEPM >8 GM [??]0.25 EM >4 CLDM >2 MINO 8 VCM 0.5 LZD [??]0.25 CPFX (LVFX) >4 ST >38/2 MIC: Minimum Inhibitory Concentration; PCG: benzylpenicillin; CTX: cefotaxime; CTRX: ceftriaxone; CFPM: cefepime; IPM: imipenem; MEPM: meropenem; GM: gentamicin; EM: erythromycin; CLDM: clindamycin; MINO: minocycline; VCM: vancomycin; LZD: linezolid; CPFX: ciprofloxacin; LVFX: levofloxacin; ST: sulfamethoxazole/trimethoprim.
Clinical Bacteria antibiotic susceptibility isolates MRSA- OXA(R)FOX(R)ERY(R)CLY(R)GEN(S)CIP(S)LVX(S)Q/D(S)LZD(R)RIF(R) GM20 MRSA- OXA(R)FOX(R)ERY(R)CLY(R)GEN(S)CIP(S)LVX(S)Q/D(S)LZD(R)RIF(R) GM31 MRSA- OXA(R)FOX(R)ERY(R)CLY(R)GEN(S)CIP(S)LVX(S)Q/D(S)LZD(R)RIF(R) GM34 OXA, oxacillin; FOX, cefoxitin; ERY, erytromycin; CLY; clindamycin; GEN, gentamicin; CIP, ciprofloxacin; LVX, levofloxacin; Q/D, quin- upristin/dalfopristin; LZD, linezolid; RIF, rifampicin.
A statistical difference was found for REMSD versus LZD + MEL + REMSD groups (* P < 0.043).
The objectives of the current post-hoc analysis were to evaluate the efficacy and safety of TZD vs LZD for the treatment of ABSSSI in patients of Latino origin enrolled into the Phase 3 ESTABLISH studies.
faecium p-value (n = 47) (n = 38) S S 23.4% 7.9% 0.05 I R 76.6% 92.1% CN S 36.2% 42.1% 0.046 I R 76.6% 57.9% AM S 100% <0.001 I R 100% IMP S 91.4% <0.001 I 4.3% R 4.3% 100% VA S 96% 65.8% <0.001 (1) I R 4% 34.2% LZD S 91.4% 100% * I R 8.6% QD S 92.1% x I 5.3% R 2.6% SXT S <0.001 I 55.3% R 44.7% 100% TGC S 97.9% 100% * I 2.1% R Antibiotic HLAR+ S/I/R E.
bethesdensis CRO/GEN/VAN, Recovered CRO/DOX/TMPSMX, CFD/DOX/TMPSMX, DOX/TMPSMX * AMK, amikacin; CAZ, ceftazidime; CFD, cefdinir; CGD, chronic granulomatous disease; CLI, clindamycin; CLR, clarithromycin; CIP, ciprofloxacin; CPD, cefpodoxime; CRO, ceftriaxone; CSP, caspofungin; CYBB, cytochrome b-245, [beta] polypeptide; DOX, doxycycline; GEN, gentamicin; HSCT, hematopoietic stem cell transplant; IFN-[gamma], interferon-[gamma]; INH, isoniazid; ITZ, itraconazole; LAMB, liposomal amphotericin B; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MTZ, metronidazole; NCF2, neutrophil cytosolic factor 2; RFB, rifabutin; RIF, rifampin; TEC, teicoplanin; TGC, tigecycline; TMPSMX, trimethoprim/sulfamethoxazole; TOB, tobramycin; VAN, vancomycin; VRZ, voriconazole.
sites/strains) VRE (%) (a) MRSA (%) (a) Rate VanA Rate LZD -S Argentina (two/498) 10 100 55 100 Brazil (five/1588) 27 89 29 100 Chile (two/467) 0 -- 68 100 Colombia (one/208) 11 31 29 100 Costa Rica (one/193) 7 100 55 100 Ecuador (one/192) 0 -- 31 100 Guatemala (one/201) 9 100 49 100 Mexico (three/1052) 26 100 48 100 Panama (one/196) 13 100 47 100 Peru (one/194) 16 100 79 100 Venezuela (two/190) 12 67 63 100 All (20/4979) 14 91 48 100 (a) EC, E.
MIC, [micro]g/mL LZD TGC VAN PEN TMP/SXT CLI SMC1101-114 0.5 <0.03 0.5 8 32/608 >32 SMC1101-127 0.5 <0.03 0.25 8 32/608 >32 SMC1103-146 0.5 <0.03 0.25 8 32/608 >32 SMC1105-235 0.5 <0.03 0.25 8 32/608 >32 SMC1108-054 0.5 <0.03 0.5 8 32/608 >32 Strain no.
Contract awarded for Supply of diesel and heating oil for lzd siemianice
faecium 1 Cholangitis Other Patient pathogens Outcome of no., age, isolated at Enterococcus y/sex DNSE site Tx infection 1/69/M None DAP Death 2/70/M None LZD, Q-D, GEN Death 3/51/M None VAN Death 4/53/F None None Undetermined 5/75/M None LZD, VAN Recovered 6/62/M E.